Committed under
Cognition Therapeutics, Inc.
$138.1 Million committed in all years on record · 0.5% of the program
- Full records
- Cognition Therapeutics, Inc. → everything they’re paid, across every program and agencyAging Research → the whole program, every recipientDepartment of Health and Human Services → everything they pay out
By fiscal year
Aging Research dollars committed to Cognition Therapeutics, Inc., per fiscal year.
* FY2026 is year-to-date — the fiscal year is still in progress, so its total is still filling in. The striped band and dashed line mark that provisional stretch.
Awards
The largest awards to Cognition Therapeutics, Inc. under this program — the top 10 of 14.
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease…
Jul 28, 2025$64.2M
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase Ii Study to Evaluate the Safety and Efficacy of CT1812 in Subjects Wit…
How to read these numbers
- Just these two
Every figure is money committed to this recipient under this one program — nothing they get anywhere else, from this program or any other.
- Totals by action year
The aggregates reflect the fiscal year picked at the top, counted in the year each action happened.
- “Active in FY X”
The award list shows every award between the two with an action that year, at its full lifetime value — so a single award's amount can top that year's committed total.
- From FY2018 on
Pairing pages start at fiscal year 2018, the first year of complete assistance reporting.
- The colored bars
Every bar on this page splits by how the money moves:
Direct paymentsGrants